



US00D934884S

(12) **United States Design Patent** (10) **Patent No.:** **US D934,884 S**
Bergental et al. (45) **Date of Patent:** **** Nov. 2, 2021**

(54) **DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE**

D633,514 S 3/2011 Tokunaga et al.
8,041,714 B2 10/2011 Aymeloglu et al.
D652,048 S 1/2012 Joseph

(Continued)

(71) Applicant: **HealthPartners Institute**, Bloomington, MN (US)

OTHER PUBLICATIONS

(72) Inventors: **Richard Mauritz Bergental**, Plymouth, MN (US); **Gregg Daniel Simonson**, Bloomington, MN (US); **Deborah Michelle Mullen**, Chattanooga, TN (US)

“AGP Reports.” AGP-Ambulatory Glucose Profile, published Oct. 20, 2018 (Retrieved from the Internet Nov. 2, 2020). Internet URL: <<https://web.archive.org/web/20181020074747/http://www.agpreport.org/agp/agpreports>> (Year: 2018).*

(Continued)

(73) Assignee: **HealthPartners Institute**, Bloomington, MN (US)

Primary Examiner — Rachel A. Voorhies

(74) *Attorney, Agent, or Firm* — Merchant & Gould P.C.

(**) Term: **15 Years**

(57) **CLAIM**

(21) Appl. No.: **29/690,827**

The ornamental design for a display screen with graphical user interface, as shown and described.

(22) Filed: **May 10, 2019**

DESCRIPTION

(51) **LOC (13) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/485**

(58) **Field of Classification Search**
USPC D14/485–495
CPC G06F 19/34; G06F 19/3418; G06F 3/048;
G06F 3/04847; G06F 1/1692; H04N
1/00424

See application file for complete search history.

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 is a front view of a first embodiment of the display screen with graphical user interface, showing a color image; and,

FIG. 2 is a front view of a second embodiment thereof. Except as indicated herein, the black dashed broken lines and dot-dot broken lines show portions of the display screen with graphical user interface that form no part of the claimed design. The dot-dash lines represent the display screen and also represent a boundary of the claimed design, and form no part of the claimed design.


The blue dashed broken lines representing 5% and 95% in the Ambulatory Glucose Profile region of FIG. 1 are part of the claimed design.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,559,868 B2	5/2003	Alexander et al.	
D519,517 S	4/2006	Reynolds et al.	
D525,264 S	7/2006	Chotai et al.	
D531,637 S *	11/2006	Chotai	D14/486
D573,601 S	7/2008	Gregov et al.	
D589,976 S	4/2009	Hosokawa et al.	
D630,648 S	1/2011	Tokunaga et al.	
D630,649 S	1/2011	Tokunaga et al.	
D632,699 S	2/2011	Judy et al.	

1 Claim, 2 Drawing Sheets
(1 of 2 Drawing Sheet(s) Filed in Color)



(56)

References Cited

U.S. PATENT DOCUMENTS

D652,052 S 1/2012 Judy et al.
 8,133,178 B2 3/2012 Brauker
 D661,313 S 6/2012 Nenoki
 D667,417 S 9/2012 Long et al.
 D674,404 S 1/2013 Percy et al.
 D674,812 S 1/2013 Joseph
 D681,651 S 5/2013 Fletcher et al.
 D684,172 S 6/2013 Rytte et al.
 D685,810 S 7/2013 Way et al.
 D690,309 S 9/2013 Wenz et al.
 D692,911 S 11/2013 Percy et al.
 D694,252 S * 11/2013 Helm D14/485
 D694,253 S * 11/2013 Helm D14/485
 D700,616 S * 3/2014 Chao D14/485
 D709,082 S 7/2014 Meegan et al.
 D709,518 S 7/2014 Meegan et al.
 D710,373 S 8/2014 Meegan et al.
 D714,327 S * 9/2014 Wood D14/485
 D717,328 S 11/2014 Lin
 D717,331 S 11/2014 Lin
 D740,847 S * 10/2015 Yampolskiy D14/486
 D756,371 S * 5/2016 Bertnick D14/485
 D756,372 S * 5/2016 Bertnick D14/485
 D757,071 S 5/2016 Kouvas et al.
 D759,073 S 6/2016 Winklevoss
 D773,478 S * 12/2016 Wesley D14/485
 D774,058 S 12/2016 Dias et al.
 D775,144 S 12/2016 Vazquez
 D778,933 S * 2/2017 Hotchkiss D14/486
 D780,199 S 2/2017 Croan
 D785,008 S 4/2017 Lim et al.
 D789,398 S * 6/2017 Akana D14/486
 D800,757 S * 10/2017 Mullen D14/486
 D802,001 S 11/2017 Javed et al.
 D804,496 S * 12/2017 Wahila D14/485
 D808,982 S * 1/2018 Kavanagh D14/485
 D809,545 S * 2/2018 Ban D14/486
 D810,100 S * 2/2018 Govindan Sankar Selvan D14/485
 D816,689 S 5/2018 Chalker et al.
 D817,977 S 5/2018 Kato et al.
 D832,865 S 11/2018 Dieken et al.
 D833,461 S 11/2018 Dieken et al.
 D835,631 S 12/2018 Yopez et al.
 D840,421 S 2/2019 Chalker et al.
 D840,427 S 2/2019 Javed et al.
 D844,633 S 4/2019 Cook
 D847,147 S * 4/2019 Wesley D14/485
 D864,219 S 10/2019 Farnan et al.
 D864,224 S 10/2019 Subrahmanian et al.
 10,606,872 B1 * 3/2020 Shelton G06F 16/24578
 D900,835 S 11/2020 Burnell et al.
 2002/0193679 A1 12/2002 Malave et al.
 2003/0216621 A1 11/2003 Alpert et al.
 2008/0127052 A1 5/2008 Rostoker
 2009/0029631 A1 1/2009 Offer et al.
 2009/0147026 A1 6/2009 Buck et al.

2009/0238597 A1 9/2009 Cao et al.
 2010/0096474 A1 4/2010 Zhang et al.
 2010/0100470 A1 4/2010 Buchanan et al.
 2012/0004947 A1 1/2012 Dombrowski et al.
 2014/0028682 A1 1/2014 Omiya
 2014/0188400 A1 7/2014 Dunn et al.
 2014/0206970 A1 7/2014 Wesley et al.
 2014/0282256 A1 * 9/2014 Fish G06F 3/04817
 715/835
 2020/0327154 A1 * 10/2020 Shelton G06F 16/24578

OTHER PUBLICATIONS

PCT International Searching Authority, International Search Report and Written Opinion dated Sep. 5, 2014 for Int'l Application No. PCT/US2014/012549, 11 pages.
 Bergenstal MD, Rich, SMBG & CGM in Clinical Practice, Barbara Davis Center Keystone Conference 2012, Jul. 15, 2012, 50 pages.
 Mazze, Roger S., Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis, Diabetes Technology & Therapeutics, vol. 10, No. 3, Jun. 1, 2008, pp. 149-159.
 Bergenstal, Ricard M. et. al, Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP), Diabetes Technology & Therapeutics 15(3), <https://www.researchgate.net/publication/235755545>, Feb. 2013, 2 pages.
 Verdecchia, Paolo et. al., Ambulatory Blood Pressure and Cardiovascular Outcome in Relation to Perceived Sleep Deprivation, <http://hyper.ahajournals.org/content/49/4/777/tab-article-info>, Mar. 21, 2011, 2 pages.
 Designing Information Systems, 1.2 Designing Information Systems, <https://saylordotorg.github.io>, Mar. 26, 2011, 3 pages.
 Wall St. Warrior, Technical Picture—Bearish Island Reversal Within a Bear Flag Pattern, <http://traderjamie.blogspot.com/2011/09/technical-picture-bearish-island.html>, Sep. 3, 2011, 2 pages.
 AGP Reports I AGP Report, agpreport.org [online], dated May 25, 2017 by Wayback Machine® (but this date is disputed by Applicant), [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: <http://www.agpreport.org/agp/agpreports>> (Year: 2017).
 First Clinical Experience with Retrospective Flash Glucose Monitoring, by Distiller et al., europepmc.org [online], published on Oct. 31, 2016, [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: <https://europepmc.org/article/med/27154973>> (Year: 2016).
 AGP CGM Report, by Carlson et al., researchgate.net [online], published on 2017-05-00, [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: https://www.researchgate.net/figure/AGP-CGM-Report-Ambulatory-Glucose-Profile-Continuous-Glucose-Monitoring-Report_fig_1_317159274> (Year: 2017).
 Pgfplots: How to Fill the Area Under a Curve, by Ferenci, tex.stackexchange.com [online], published on Sep. 24, 2011, [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: <https://tex.stackexchange.com/questions/29359/pgfplots-how-to-fill-the-area-under-a-curve-with-oblique-lines-hatching-as-a>> (Year: 2011).

* cited by examiner

AGP Report

Name

MRN

GLUCOSE STATISTICS AND TARGETS


26 Feb 2019-10 Mar 2019 15 days
% Time CGM is Active 99.9%

Glucose Ranges	Targets [% of Readings (Time/Day)]
Target Range 70-180 mg/dL	Greater than 70% (16hr 48min)
Below 70 mg/dL	Less than 4% (58min)
Below 54 mg/dL	Less than 1% (14min)
Above 250 mg/dL	Less than 5% (1hr 12min)

Each 5% increase in time in range (70-180 mg/dL) is clinically beneficial.


Average Glucose 178 mg/dL
Glucose Management Indicator (GMI) 7.9%
Glucose Variability 40.8%
 Defined as percent coefficient of variation (%CV); target $\leq 36\%$

TIME IN RANGES




AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



DAILY GLUCOSE PROFILES



Each daily profile represents a midnight-to-midnight period.

captiOrAGP®

FIG. 1

AGP Report

Name _____

MRN _____

GLUCOSE STATISTICS AND TARGETS


26 Feb 2019-10 Mar 2019 **15 days**
% Time CGM is Active 89.9%

Glucose Ranges	Targets [% of Readings (Time/Day)]
Target Range 70-180 mg/dL	Greater than 70% (16hr 48min)
Below 70 mg/dL	Less than 4% (58min)
Below 54 mg/dL	Less than 1% (14min)
Above 250 mg/dL	Less than 5% (1hr 12min)

Each 5% increase in time in range (70-180 mg/dL) is clinically beneficial.


Average Glucose 172 mg/dL
Glucose Management Indicator (GMI) 7.6%
Glucose Variability 49.5%
 Defined as percent coefficient of variation (%CV); target $\leq 36\%$

TIME IN RANGES




AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



DAILY GLUCOSE PROFILES



Each daily profile represents a midnight-to-midnight period.

capturAGP[®]

FIG. 2